TD Cowen has reaffirmed United Therapeutics as one of its top picks, maintaining a Buy rating and a $675 price target after meeting with the company's senior management. The investment firm said the discussions left it confident in United Therapeutics' potential for meaningful growth driven by pipeline progress and expansion of existing franchises.
At an investor dinner, UTHR executives expressed strong optimism about Tyvaso - their inhaled therapy - particularly its potential in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis. Management indicated that Phase III data for those indications could arrive as early as next year, a development TD Cowen flagged as material to the company's growth trajectory.
Executives described Tyvaso's move into fibrotic lung disease as likely to be a significant growth driver beyond its established pulmonary hypertension franchise. The company also highlighted ralinepag, which management presented as a once-daily oral candidate for pulmonary arterial hypertension (PAH). According to the discussion, a new drug application for ralinepag was expected this month, and the firm is considering developing an inhaled dry-powder form to broaden the therapy's reach and extend the franchise.
Beyond these programs, UTHR management reviewed progress in its xenotransplantation efforts. TD Cowen noted that this program has continued to advance steadily, although it has attracted relatively little investor attention so far.
The equity research firm emphasized that the company's pipeline candidates represent sizeable potential revenue levers in the quarters ahead, particularly if late-stage clinical testing produces favorable outcomes.
Capital allocation and financial outlook
Management told investors that it remains open to acquisitions that align with United Therapeutics' therapeutic focus and that deliver both commercial value and patient benefits. Share repurchases remain under consideration as well.
Executives said they expect expenses to lag revenue growth, a dynamic they believe will support stronger free cash flow toward the end of the decade. In line with that outlook, UTHR management reaffirmed guidance calling for double-digit revenue growth this year and signaled an expectation of further acceleration through 2026 as the company prepares for product launches anticipated in 2027.
Recent results and clinical milestones
In recent company-reported results, United Therapeutics posted first-quarter revenue of $781.5 million, a figure that fell short of analyst estimates. On the clinical front, the firm's TETON-1 Phase III study of Tyvaso met its primary endpoint for treating idiopathic pulmonary fibrosis, a key development the company has highlighted.
TD Cowen's decision to maintain its Buy rating and price target reflects the firm's assessment of United Therapeutics' near-term catalysts - from potential late-stage readouts to regulatory filings and formulation work - together with management's capital allocation plans.
Bottom line
Following the management meeting, TD Cowen continues to view United Therapeutics as positioned for growth based on its pipeline expansion and franchise development strategies, while management emphasizes both potential product launches and prudent capital deployment as drivers of future value.